34th Annual CFS™ Chemotherapy Foundation Satellite Symposium^®

Friday, November 11, 2016
8:30AM - 10:00 AM
CME-Certified Concurrent Symposium - Live Taping: Renal Cell Carcinoma in an Era of Rapid Discovery:
Key Questions
 
New York Marriott Marquis
1535 Broadway
New York, NY 10036
Room: Julliard Complex (5th Floor)
 

Registration

Registration is complimentary, but seating is limited. Please register here.
 
 
Overview

This edition of Medical Crossfire®, filmed in conjunction with the 34^th Annual CFS^™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, is designed to provide a dynamic discussion of current and evolving paradigms in the treatment of advanced renal cell carcinoma (RCC), including therapeutic sequencing, new targeted and immunotherapeutic agents, TKI resistance, and individualization of therapy. The Activity Chair, Robert Figlin, MD, along with our expert faculty, will emphasize the cutting-edge clinical research that is already shaping their practice, or is likely to do so in the not-too-distant future.
 
During this 60-minute CME-certified activity, the faculty will exchange perspectives and opinions on 5 key clinically relevant questions related to therapeutic resistance, newly approved therapeutics, recently reported long-term overall survival data, subgroup analyses from landmark studies, treatment selection and sequencing, as well as real-world experiences with treatment-related side effects. 

Target Audience
This activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and urologists who treat patients with renal cell carcinoma (RCC). Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare providers who are interested in the care of patients with RCC may also attend.
 

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

• Explain targeted and immunotherapeutic mechanistic approaches to overcome anti-angiogenic resistance in the management of RCC
• Describe evidence-based approaches that inform optimized sequencing of current and emerging strategies for RCC
• Discuss proactive measures to manage and mitigate treatment-related side effects associated with approaches for advanced RCC
• Critically evaluate recent clinical trial data in the context of the established evidence guiding individualized treatment planning for patients with advanced RCC

 
 
Activity Chair

Robert A. Figlin, MD, FACP Steven Spielberg Family Chair in Hematology Oncology Professor of Medicine and Biomedical Sciences Director, Division of Hematology Oncology Deputy Director Samuel Oschin Comprehensive Cancer Institute                                   Cedars-Sinai Medical Center

 

Faculty

David F. McDermott, MD Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program Director, Biologic Therapy and Cutaneous Oncology Programs, Beth Israel Deaconess Medical Center Associate Professor of Medicine, Harvard Medical School Boston,

Robert . Motzer, MD, MPH Memorial Sloan Kettering Cancer Center Oncology Specialist Memorial Sloan Kettering Cancer New York, NY

Elizabeth Plimack, MD, MS Chief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Associate Professor, Department of Hematology/Oncology Fox Chase Cancer Center

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Aknowledgement of Commercial Support

This activity is supported by an educational grant from Exelixis, Inc.
 

Photos from the 34th Annual CFS™ Chemotherapy Foundation Satellite Symposium^®